Found: 83
Select item for more details and to access through your institution.
Correction: Donanemab: First Approval.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Donanemab: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 10, p. 1313, doi. 10.1007/s40265-024-02087-4
- By:
- Publication type:
- Article
Correction to: Several more myasthenia gravis therapy options now available.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Consider microscopic colitis in older adults presenting with chronic, non-bloody, watery diarrhoea.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 10, p. 401, doi. 10.1007/s40267-024-01103-7
- By:
- Publication type:
- Article
11.2: Invited Paper: Study of Green LED Growth for Advanced Display Applications.
- Published in:
- SID Symposium Digest of Technical Papers, 2022, v. 53, p. 124, doi. 10.1002/sdtp.15868
- By:
- Publication type:
- Article
55.5: AMEC MOCVD Solution of Mini/Micro‐LEDs for Advanced Display Applications.
- Published in:
- SID Symposium Digest of Technical Papers, 2021, v. 52, p. 668, doi. 10.1002/sdtp.15242
- By:
- Publication type:
- Article
In vitro and in silico genetic toxicity screening of flavor compounds and other ingredients in tobacco products with emphasis on ENDS.
- Published in:
- Journal of Applied Toxicology, 2020, v. 40, n. 11, p. 1566, doi. 10.1002/jat.4020
- By:
- Publication type:
- Article
Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 4, p. 451, doi. 10.1007/s40256-022-00538-5
- By:
- Publication type:
- Article
Investment and Productivity in Canadian and U.S. Food Manufacturing.
- Published in:
- Canadian Journal of Agricultural Economics, 1999, v. 47, n. 2, p. 105, doi. 10.1111/j.1744-7976.1999.tb00385.x
- By:
- Publication type:
- Article
Digital agriculture platforms: Driving data‐enabled agricultural innovation in a world fraught with privacy and security concerns.
- Published in:
- Agronomy Journal, 2022, v. 114, n. 5, p. 2635, doi. 10.1002/agj2.20873
- By:
- Publication type:
- Article
Sotatercept: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 7, p. 857, doi. 10.1007/s40265-024-02058-9
- By:
- Publication type:
- Article
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 579, doi. 10.1007/s40265-024-02027-2
- By:
- Publication type:
- Article
Danicopan: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 5, p. 613, doi. 10.1007/s40265-024-02023-6
- By:
- Publication type:
- Article
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Lumasiran: A Review in Primary Hyperoxaluria Type 1.
- Published in:
- Drugs, 2024, v. 84, n. 2, p. 219, doi. 10.1007/s40265-023-01987-1
- By:
- Publication type:
- Article
Avacincaptad Pegol: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1447, doi. 10.1007/s40265-023-01948-8
- By:
- Publication type:
- Article
Retifanlimab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 731, doi. 10.1007/s40265-023-01884-7
- By:
- Publication type:
- Article
Ravulizumab: A Review in Generalised Myasthenia Gravis.
- Published in:
- Drugs, 2023, v. 83, n. 8, p. 717, doi. 10.1007/s40265-023-01877-6
- By:
- Publication type:
- Article
Keverprazan Hydrochloride: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 639, doi. 10.1007/s40265-023-01865-w
- By:
- Publication type:
- Article
Olutasidenib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 4, p. 341, doi. 10.1007/s40265-023-01844-1
- By:
- Publication type:
- Article
Teclistamab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 16, p. 1613, doi. 10.1007/s40265-022-01793-1
- By:
- Publication type:
- Article
Mosunetuzumab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1229, doi. 10.1007/s40265-022-01749-5
- By:
- Publication type:
- Article
Maribavir: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 3, p. 335, doi. 10.1007/s40265-022-01677-4
- By:
- Publication type:
- Article
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis.
- Published in:
- Drugs, 2022, v. 82, n. 1, p. 55, doi. 10.1007/s40265-021-01650-7
- By:
- Publication type:
- Article
Correction to: Infigratinib: First Approval.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Infigratinib: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 11, p. 1355, doi. 10.1007/s40265-021-01567-1
- By:
- Publication type:
- Article
Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
- Published in:
- Drugs, 2021, v. 81, n. 8, p. 945, doi. 10.1007/s40265-021-01527-9
- By:
- Publication type:
- Article
Fosdenopterin: First Approval.
- Published in:
- Drugs, 2021, v. 81, n. 8, p. 953, doi. 10.1007/s40265-021-01520-2
- By:
- Publication type:
- Article
Bulevirtide: First Approval.
- Published in:
- Drugs, 2020, v. 80, n. 15, p. 1601, doi. 10.1007/s40265-020-01400-1
- By:
- Publication type:
- Article
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
- Published in:
- Drugs, 2020, v. 80, n. 6, p. 601, doi. 10.1007/s40265-020-01295-y
- By:
- Publication type:
- Article
Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer.
- Published in:
- Drugs, 2019, v. 79, n. 14, p. 1583, doi. 10.1007/s40265-019-01195-w
- By:
- Publication type:
- Article
Consider the many different ways to manage neuropathic pain in patients with multiple sclerosis, but more evidence is needed.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 9, p. 363, doi. 10.1007/s40267-024-01102-8
- By:
- Publication type:
- Article
Include rare, treatable IL-1-mediated autoinflammatory diseases in differential diagnosis of chronic or periodic inflammation.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 9, p. 353, doi. 10.1007/s40267-024-01096-3
- By:
- Publication type:
- Article
Several more myasthenia gravis therapy options now available.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 9, p. 350, doi. 10.1007/s40267-024-01095-4
- By:
- Publication type:
- Article
Suspect cutaneous lupus erythematous in older patients with photosensitive rash.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 216, doi. 10.1007/s40267-024-01080-x
- By:
- Publication type:
- Article
Add or switch to systemics and biologics where topical paediatric hidradenitis suppurativa therapy fails.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 6, p. 211, doi. 10.1007/s40267-024-01076-7
- By:
- Publication type:
- Article
Dietary supplements may boost memory, but more evidence is required.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 5, p. 185, doi. 10.1007/s40267-024-01070-z
- By:
- Publication type:
- Article
Aim to alleviate alopecia areata with newly available agents.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 5, p. 181, doi. 10.1007/s40267-024-01069-6
- By:
- Publication type:
- Article
Determine and remove the drug trigger, usually antibiotics, that causes acute generalised exanthematous pustulosis.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 4, p. 141, doi. 10.1007/s40267-024-01064-x
- By:
- Publication type:
- Article
Sparsentan in immunoglobulin A nephropathy: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 3, p. 101, doi. 10.1007/s40267-024-01058-9
- By:
- Publication type:
- Article
Get on top of gout with a fresh look at treatment options.
- Published in:
- Drugs & Therapy Perspectives, 2024, v. 40, n. 3, p. 115, doi. 10.1007/s40267-024-01063-y
- By:
- Publication type:
- Article
Manage truncal acne and scarring the same as for facial acne, but more trunk-specific therapies are warranted.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 9, p. 324, doi. 10.1007/s40267-023-01018-9
- By:
- Publication type:
- Article
Prescribe colchicine with care and be aware of colchicine drug interactions.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 10, p. 348, doi. 10.1007/s40267-023-01024-x
- By:
- Publication type:
- Article
Consider new therapies for the treatment and prevention of Clostridioides difficile infection.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 7, p. 237, doi. 10.1007/s40267-023-01006-z
- By:
- Publication type:
- Article
Manage seborrhoeic dermatitis in older adults with customised regimens that address age-related factors.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 7, p. 232, doi. 10.1007/s40267-023-01004-1
- By:
- Publication type:
- Article
Risk of falls and fractures does not necessarily preclude the use of antihypertensive medications.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 6, p. 212, doi. 10.1007/s40267-023-00999-x
- By:
- Publication type:
- Article
Treat hyperhidrosis with topical therapies first, then dermatological or systemic therapies.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 6, p. 200, doi. 10.1007/s40267-023-00996-0
- By:
- Publication type:
- Article